Valuation: Insmed Incorporated

Market Cap 27.07B 23.61B 22.29B 20.24B 37.93B 2,598B 38.09B 267B 103B 1,321B 102B 99.45B 4,250B P/E 2026 *
-75.7x
P/E 2027 * 167x
Enterprise Value 26.44B 23.06B 21.77B 19.77B 37.04B 2,537B 37.2B 261B 101B 1,290B 99.33B 97.13B 4,151B EV / Sales 2026 *
14.6x
EV / Sales 2027 * 9.03x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week-5.93%
Current month-0.07%
1 month-5.24%
3 months+27.07%
6 months-14.70%
Current year-30.06%
1 week 118.34
Extreme 118.34
130.78
1 month 117.15
Extreme 117.15
131.1
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%-5.93%-16.54%+358.49% 27.07B
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+2.06%+40.91%+78.49% 62.32B
-2.55%-0.48%-0.05%-11.72% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.31%+3.78%+43.98%+172.79% 14.49B
-0.73%+0.20%-8.55%+871.55% 14.14B
-0.15%-0.20%+21.03%+226.09% 12.35B
-1.82%-6.93%+39.30%+102.72% 9.72B
Average -0.80%+1.01%+36.44%+217.62% 27.19B
Weighted average by Cap. -0.55%+1.16%+35.89%+162.88%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.49B 1.35B 2.53B 173B 2.54B 17.82B 6.88B 88.13B 6.79B 6.64B 284B 2.87B 2.5B 2.36B 2.15B 4.02B 275B 4.04B 28.31B 10.92B 140B 10.78B 10.54B 451B
Net income -350M -306M -289M -262M -491M -33.63B -493M -3.46B -1.33B -17.1B -1.32B -1.29B -55.01B 187M 163M 154M 139M 261M 17.9B 262M 1.84B 710M 9.1B 701M 685M 29.28B
Net Debt -632M -551M -520M -472M -885M -60.63B -889M -6.23B -2.4B -30.82B -2.37B -2.32B -99.18B -1.16B -1.01B -952M -865M -1.62B -111B -1.63B -11.41B -4.4B -56.43B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
18/09/26 $121.61 -1.91% 1,045,141
17/09/26 $123.98 +1.14% 1,592,254
16/09/26 $122.58 +2.22% 1,434,017
15/09/26 $119.92 -4.29% 3,364,508
14/09/26 $125.30 -3.18% 1,610,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
123.98USD
Average target price
199.55USD
Spread / Average Target
+60.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!